Prevention and treatment of upper respiratory diseases in the pandemic COVID-19 era.

Passali, D; Bellussi, L M; Passali, F M; De Hoyos, R; Di Girolamo, S; Ciprandi, G

Passali, D; Bellussi, L M; Passali, F M; De Hoyos, R; Di Girolamo, S; Ciprandi, G.

Afiliação

Passali D; International Federation ORL Societies (IFOS) Executive Board members, Rome, Italy.
Bellussi LM; International Federation ORL Societies (IFOS) Executive Board members, Rome, Italy.
Passali FM; ENT Department, University Tor Vergata, Rome, Italy.
De Hoyos R; Departamento de Ciencias Clínicas (Escuela de Medicina), Tecnológico de Monterrey, Monterrey, Mexico.
Di Girolamo S; ENT Department, University Tor Vergata, Rome, Italy.
Ciprandi G; Consultant allergist, Clinic, Casa di Cura Villa Montallegro, Genoa, Italy.

J Biol Regul Homeost Agents ; 35(1 Suppl. 2): 3-8, 2021.

Article em En | MEDLINE | ID: mdl-33982531

Assuntos

COVID-19; Pandemias; Suplementos Nutricionais; Humanos; SARS-CoV-2; Vitaminas

Palavras-chave

COVID-19; bacteriotherapy; microbiota; nutraceuticals; oligo-elements; upper respiratory infections

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pandemias / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pandemias / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article